In a newly announced partnership with Texas biotech company Colossal Biosciences, Australian researchers are hoping their dream to bring back the extinct thylacine is a “giant leap” closer to fruition.
Scientists at University of Melbourne’s TIGRR Lab (Thylacine Integrated Genetic Restoration Research) believe the new partnership, which brings Colossal’s expertise in CRISPR gene editing on board, could result in the first baby thylacine within a decade.
The genetic engineering firm made headlines in 2021 with the announcement of an ambitious plan to bring back something akin to the woolly mammoth, by producing elephant-mammoth hybrids or “mammophants”.
But de-extinction, as this type of research is known, is a highly controversial field. It’s often criticised for attempts at “playing God” or drawing attention away from the conservation of living species. So, should we bring back the thylacine? We asked five experts.
This article is republished from The Conversation is the world's leading publisher of research-based news and analysis. A unique collaboration between academics and journalists.